Company Overview
Our Science
- Our Science
- Posters & Publications
Clinical Pipeline
- Clinical Pipeline
- Clinical Trials
Investors & Media
Contact
- Contact
- Patient Contact
Follow Us
- LinkedIn
- X
- Facebook
- Youtube
- Sign Up for Updates

Company Overview

Company Overview Leadership Team Corporate Governance Partnering Career

Our Science

Our Science Posters & Publications

Clinical Pipeline

Clinical Pipeline Clinical Trials

Investors & Media

Investors & Media Press Releases ASX Announcements SEC Filings In the News & Media Events Presentations Analyst Reports Financial Reports FAQ

Contact

Contact Patient Contact

Follow Us

LinkedIn X Facebook Youtube Sign Up for Updates

Press releases.

CTOS 2024 Annual Meeting – EFTISARC-NEO trial of neoadjuvant soluble LAG-3 protein (Soft Tissue Sarcoma)

November 13, 2024

Company Overview
Leadership Team
Corporate Governance
Partnering
Career

Our Science
Posters & Publications

Clinical Pipeline
Clinical Trials

Investors & Media
Press Releases
ASX Announcements
SEC Filings
In the News & Media
Events
Presentations
Analyst Reports
Financial Reports
FAQ

Contact
Patient Contact

Australian Investors/Media:

Eleanor Pearson, Sodali & Co.
Ph: +61 2 9066 4071;
eleanor.pearson@sodali.com

US Investor Relations
Ph: +1 (631) 318-4000
chris.basta@immutep.com

© 2025 Immutep. All rights reserved.

Immutep Limited
Level 32, Australia Square
264 George Street
SYDNEY NSW 2000
AUSTRALIA

Ph: +61 2 8315 7003
Fax: +61 2 8569 1880
enquiries@immutep.com

Imprint
Privacy Policy
Terms of Use

© 2025 Immutep. All rights reserved.

© 2025 Immutep. All rights reserved.

Imprint
Privacy Policy
Terms of Use